로딩 중…
지수 로딩 중…
NGeneBio Co., Ltd.
354200· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩792-9.38%
2026-06-19
Price Chart
NGeneBio Co., Ltd.-61.92%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 21.23B KRW |
| Revenue | 31.16B KRW |
| Net Income | -8.23B KRW |
| Total Assets | 71.69B KRW |
| Net Assets | 22.12B KRW |
| Employees | 96 |
| Value | |
| P/B | 0.96x |
| P/S | 0.68x |
| FCF Yield | -40.22% |
| Profitability | |
| ROE | -37.19% |
| ROA | -11.48% |
| Op. Margin | -22.41% |
| Revenue Growth | 487.11% |
| Financial Health | |
| Debt Ratio | 324.10% |
| Total Debt | 32.25B KRW |
| FCF | -8.54B KRW |
| Cash | 2.97B KRW |
| Current Ratio | 0.48x |
| Performance | |
| 1Y Return | -61.92% |
| 1M Return | -34.44% |
| From 52W High | -71.36% |
| 1Y MDD | -69.94% |
| Trading | |
| Volume | 215,293 shares |
| Foreign Own. | 1.76% |
| Per Share | |
| EPS | -291 KRW |
| BPS | 842 KRW |
Company Info
Established in 2015, NGENBIO is a specialized NGS-based precision diagnostics company. It was listed on the KOSDAQ market in 2020 and expanded its pharmaceutical distribution business through an acquisition in 2025. The company provides gene extraction panels and data analysis software for conditions like breast cancer and blood cancer, and operates toxicology and molecular diagnostics services. NGENBIO supplies products to over 25 major medical institutions in Korea, expands overseas exports, and is leading the precision medicine market. NGENBIO is headquartered in Guro-gu, Seoul.